Key Highlights

Risk & Performance

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Phase 3

3(75.0%)

Phase 2

1(25.0%)

4Total

Phase 3(3)

Phase 2(1)

Loading network data...

Showing 4 of 4 trials

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Role: collaborator

Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer

Role: collaborator

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

Role: collaborator

Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

Role: collaborator

All 4 trials loaded